<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537342</url>
  </required_header>
  <id_info>
    <org_study_id>2006-001130-41</org_study_id>
    <secondary_id>6018-PG-OSL-142</secondary_id>
    <nct_id>NCT00537342</nct_id>
  </id_info>
  <brief_title>Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)</brief_title>
  <official_title>Prospective, Randomised, Double Blind, Placebo Controlled Study of Treatment With Sublingual Immunotherapy of Depigmented and Polymerised Allergen Extract of O. Europaea in Two Groups of Patients With Allergic Rhinitis /Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the clinical effectiveness of the administration&#xD;
      of a depigmented and polymerized allergen extract of Olea europaea in the rhinitis or&#xD;
      allergic rhinoconjunctivitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy is a specific treatment for allergic diseases. Unlike conventional&#xD;
      pharmacological treatment, immunotherapy is the only treatment that could modify the natural&#xD;
      course of allergic disease. This is a prospective double-blind placebo controlled study with&#xD;
      two arms of treatment: placebo and active.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom score</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-response skin prick-test</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis quality of life questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analogical visual scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Allergy</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy with modified extract of O. europaea pollen</intervention_name>
    <description>Sublingual (2 drops daily during 2 months)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive suggestive clinical history of allergic seasonal rhinitis or&#xD;
             rhinoconjunctivitis&#xD;
&#xD;
          -  Patients of both gender &gt; 18 years old&#xD;
&#xD;
          -  Positive prick test results using non modified Olea europaea allergen extract (wheal&#xD;
             size &gt; 3mm2)&#xD;
&#xD;
          -  Specific IgE to Olea europaea&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of immunotherapy during the last four years.&#xD;
&#xD;
          -  Any contraindication for the use of immunotherapy in accordance with European Allergy&#xD;
             and Clinical Immunology Immunotherapy Subcommittee criteria:&#xD;
&#xD;
          -  Treatment with ß-blockers&#xD;
&#xD;
          -  Coexistence of immunopathological diseases (e.g. of the liver, kidney, the nervous&#xD;
             system, thyroid gland, rheumatic diseases) in which autoimmune mechanisms play a role&#xD;
&#xD;
          -  Patients suffering from immune deficiencies&#xD;
&#xD;
          -  Patients with serious psychiatric / psychological disturbances&#xD;
&#xD;
          -  In addition, the following was considered as exclusion criteria:&#xD;
&#xD;
          -  Pregnant or/ in lactation patients&#xD;
&#xD;
          -  Patients aspirin intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Luis Anguita, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitatio Ciudad de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mª José Gómez</name_title>
    <organization>Laboratorios LETI S.L.Unipersonal</organization>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Allergoid</keyword>
  <keyword>Depigmented</keyword>
  <keyword>Polymerized</keyword>
  <keyword>Allergen-extract</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

